secretagogue comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-09-01. Numbers and descriptions here follow the published literature rather than marketing material.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue family. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, incorporating two non-natural residues that resist enzymatic breakdown. Researchers at Novo Nordisk described the compound in the 1990s while searching for agents that release growth hormone with fewer side effects than earlier secretagogues. The molecule acts as an agonist at the ghrelin receptor, also called GHS-R1a, which is expressed in the pituitary and in several peripheral tissues.
Selectivity distinguishes ipamorelin from first-generation secretagogues such as GHRP-6. At doses that reliably raise growth hormone, it shows little stimulation of adrenocorticotropic hormone or cortisol release in animal models, and it does not markedly raise prolactin or appetite. Binding at GHS-R1a on pituitary somatotrophs triggers calcium influx and pulsatile growth hormone secretion. Because the compound mimics the natural ghrelin signal, the release pattern tends to follow the body's own rhythm rather than producing a sustained elevation.
Peptides such as ipamorelin are subject to chemical and physical degradation. Hydrolysis of peptide bonds, oxidation of susceptible residues, and aggregation are common pathways that reduce purity over time. The rate of these processes depends on temperature, moisture, pH, and the number of freeze-thaw cycles a sample undergoes. Because the compound is typically handled as a lyophilized powder, controlling moisture during storage is a central concern. Degradation products can be detected with separation techniques that resolve the parent peptide from related impurities.
Lyophilized material is generally stored frozen and protected from light and moisture. Typical recommendations place dry powder at temperatures well below freezing, while reconstituted solutions are kept cold and used within a defined window. Repeated freezing and thawing should be avoided because it can promote aggregation and loss of material. The choice of solvent matters as well; compatibility with the intended diluent should be checked before preparation. These handling practices aim to preserve both the quantity and the integrity of the peptide.
Verification of identity and purity relies on analytical methods used across peptide chemistry. Reverse-phase high-performance liquid chromatography separates components by hydrophobicity and provides a purity estimate. Mass spectrometry confirms molecular mass and helps detect modifications. Together these techniques give complementary information about whether a sample matches its expected structure. Results depend on method parameters and reference standards, so reported purity values are meaningful only when the analytical conditions are stated. Consistency between laboratories requires comparable protocols and well-characterized reference materials.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C38H49N9O5 | Includes two non-natural residues |
| Molecular weight | About 711.9 g/mol | Confirmed by mass spectrometry |
| Appearance | White to off-white powder | Typical lyophilized form |
| Receptor target | GHS-R1a | Ghrelin receptor agonist |
| Plasma half-life | Roughly 2 hours | Varies by species and assay |
The compound was developed at Novo Nordisk during the 1990s as part of a programme seeking secretagogues with improved selectivity. It was described in the peer-reviewed literature in 1998 alongside related pentapeptides from the same series. Investigators advanced it because it raised growth hormone output in animal models while leaving other pituitary hormones comparatively unaffected. The development code NNC 26-0161 appears in earlier reports, and ipamorelin later became the common designation in published work.
Selectivity is the property most often attached to this peptide. Published animal and early human studies record increases in growth hormone release after administration, with adrenocorticotropic hormone and cortisol responses remaining small by comparison. Effects on appetite-related pathways also appear weaker than those reported for several earlier secretagogues. Reviews that compare members of the growth hormone secretagogue family cite these findings frequently, though the receptor-level explanation for the selectivity continues to be debated rather than settled.
Identity and purity assessment for a research peptide of this kind typically combines reversed-phase high-performance liquid chromatography with mass spectrometry. The chromatographic run separates related impurities and yields a purity percentage, while electrospray ionization or matrix-assisted laser desorption mass spectrometry confirms the expected molecular mass. Amino acid analysis or tandem mass spectrometry sequencing can add confidence when material is intended for quantitative work. Laboratories differ in how they calculate and report purity, so figures from different sources are not always directly comparable.
Lyophilized material is generally stored cold and dry, with desiccant, and protected from light. In solution the peptide is more vulnerable: the histidine side chain can oxidize, and repeated freeze-thaw cycles promote aggregation and loss of material to container surfaces. A mildly acidic aqueous buffer is often used for short-term handling because it limits several degradation routes. Accurate prediction of long-term stability under a given set of conditions is difficult, and published stability data remain sparse.
Published discussion of this compound is uneven. Some references describe it as a tool for probing growth hormone regulation, while others focus on analytical characterization or on comparisons with related secretagogues. Statements about selectivity, half-life and potency often trace back to a small number of original reports that later authors cite secondhand. Readers evaluating a claim should therefore check whether a figure reflects a direct measurement or a repeated citation, and whether the underlying study was conducted in animals, in isolated cells or in human volunteers.
Research quantities of ipamorelin are typically distributed as a white to off-white lyophilized powder. The solid dissolves readily in water and in aqueous buffers, and stock solutions are commonly prepared in sterile water or a mildly acidic diluent. Adsorption to plastic and glass surfaces can reduce the concentration of very dilute solutions, so containers and transfer steps deserve attention when accurate concentrations matter. Reconstituted material is generally used promptly rather than held for extended periods.
Storage recommendations for the dry solid center on low temperature and low moisture, most often -20 °C in a sealed, desiccated container protected from light. Solutions are less stable than the powder and are usually kept cold and used within a short window. Freeze-thaw cycling is a recognized source of loss, and aliquoting before freezing is a standard precaution. These practices derive from general peptide handling principles rather than from a single published stability trial, so exact shelf lives should be treated as approximate.
Analytical confirmation relies on reversed-phase high-performance liquid chromatography, often coupled to mass spectrometry for identity and purity assessment. Mass spectrometry distinguishes the intact molecule from truncation products and from oxidation or deamidation variants that share similar chromatographic retention. Immunoassays appear in some biological studies but can cross-react with related peptides, so they are weaker tools for identity work. Reported purity figures depend heavily on the gradient, detector, and integration method used, which complicates direct comparison between laboratories.
At the molecular level, ipamorelin acts as an agonist at the growth hormone secretagogue receptor type 1a, the same G protein-coupled receptor that binds ghrelin. Receptor activation couples to Gq/11 signaling, raising intracellular calcium through inositol trisphosphate and diacylglycerol, which in turn promotes exocytosis of growth hormone from pituitary somatotroph cells. Ipamorelin binds this receptor with high affinity and shows weak activity at other secretagogue-related targets in vitro. Its action requires the intact receptor and is not reversed by growth hormone-releasing hormone antagonists.
Compared with earlier growth hormone secretagogues such as GHRP-6 and hexarelin, ipamorelin has been reported to produce less stimulation of adrenocorticotropic hormone, cortisol, and prolactin in animal and early human studies. This selectivity is usually attributed to differences in receptor subtype interactions and to the tissue distribution of the receptor. Effects on appetite appear weaker than those of ghrelin itself, although the supporting evidence base is small. Whether these differences produce a distinct clinical profile remains an open question, since controlled human trials are limited.
After neighbors reported the crime and named Karriem as a likely suspect, Karriem and wife Bertha (35) were arrested at 2729 Clinton street. In custody, Karriem admitted to the slayings. Karriem told police: "I had to kill somebody, I could not forsake my gods". Karriem reportedly told police "The ninth hour of the twentieth day had come Sunday. It was predestined 1,500 years ago that at that hour I must make a human sacrifice to my gods. It must not be a member of the Order of Islam." Karriem claimed Smith assented to the sacrifice, telling police "At first he didn't want to be killed, but when I showed him that he would be the saviour of the world and go to heaven right away, he said all right." Press on November 21 reported Karriem was the self-described "King" of a 100-member cult. Police initially suspected Karriem might be tied to the 1929 slaying of Benny Evangelista, whom press called a cult leader. Press ran a second story on the practice of Voodoo. Karriem explained "Smith was sitting in a chair in front of the altar. My wife was time-keeper. As the hour drew near, I said, 'Smith, do you still want to be killed?' because the command ordered me not to kill anybody who didn't want to be killed. Smith nodded his head. When it was just 12 o'clock, I said, 'Smith, get up and stand on the altar.' I grabbed my dirk (an eight-inch case knife) and stabbed him like this. Smith fell off the altar and started to groan and tried to get up.
Which plants have which types of defense? Which herbivores, specifically, are the plants defended against? What chemical structures and mechanisms of toxicity are involved in the compounds that provide defense? What are the potential medical uses of these compounds? These questions and others constitute an active area of research in modern botany, with important implications for understanding plant evolution and medical science. Below is an extensive, if incomplete, list of plants containing one or more poisonous parts that pose a serious risk of illness, injury, or death to humans or domestic animals. There is significant overlap between plants considered poisonous and those with psychotropic properties, some of which are toxic enough to present serious health risks at recreational doses. There is a distinction between plants that are poisonous because they naturally produce dangerous phytochemicals, and those that may become dangerous for other reasons, including but not limited to infection by bacterial, viral, or fungal parasites; the uptake of toxic compounds through contaminated soil or groundwater; and/or the ordinary processes of decay after the plant has died; this list deals exclusively with plants that produce phytochemicals. Many plants, such as peanuts, produce compounds that are only dangerous to people who have developed an allergic reaction to them, and with a few exceptions, those plants are not included here (see list of allergens instead).
An association between osteoporosis, another disease characterized by the degradation of bony tissue, and sarcopenia, the age-related degeneration of muscle mass and quality have also been found. Whether this link is a result of direct regulation or a secondary effect through muscle mass is not known. A link in mice between the concentration of myostatin in the prenatal environment and the strength of offspring's bones, partially counteracting the effects of osteogenesis imperfecta (brittle bone disease) has been found. Osteogenesis imperfecta is due to a mutation that causes the production of abnormal Type I collagen. Mice with defective myostatin were created by replacing sequences coding for the C-terminal region of myostatin with a neomycin cassette, rendering the protein nonfunctional. By crossbreeding mice with the abnormal Type I collagen and those with the knockout myostatin, the offspring had "a 15% increase in torsional ultimate strength, a 29% increase in tensile strength, and a 24% increase in energy to failure" of their femurs as compared to the other mice with osteogenesis imperfecta, showing the positive effects of decreased myostatin on bone strength and formation.
Sources: en.wikipedia.org
=== Mean lifetime === If the decaying quantity, N(t), is the number of discrete elements in a certain set, it is possible to compute the average length of time that an element remains in the set. This is called the mean lifetime (or simply the lifetime), where the exponential time constant,
Both the δDs of sea water and the fractionations associated with hyptophyte biochemistry (εbio) are fairly well understood, so alkenones can be readily used to observe the secondary effect of salinity on δD. There is a well established positive linear correlation between salinity and εl/w, on the order of a ~3‰ change in fractionation per salinity unit. Hypothesized mechanisms for this effect include enrichment of D in intracellular water due to reduced exchange with extracellular water at higher salinity, removal of H from intracellular water due to increased production of solutes to maintain osmotic pressure at higher salinity, and lower haptophyte growth rates at higher salinity Alkenone δDs have been used successfully to reconstruct past salinity changes in the Mediterranean Sea, Black Sea, Panama Basin, and Mozambique Channel. As an extension of salinity, this data was also used to draw further conclusions about ancient environments, such as ancient freshwater flooding events, and the evolution of plankton in response to environmental changes
These experiments are designed to clone and express transporter genes in host cells to further analyze the three-dimensional structure of uniporters, as well as directly observe the movement of ions through proteins in real-time. The discovery of mutations in uniporters has been linked to diseases such as GLUT1 deficiency syndrome, cystic fibrosis, Hartnup disease, primary hyperoxaluria and hypokalemic periodic paralysis.
Agilent ChemStation is a software package to control Agilent liquid chromatography, gas chromatography, and ultraviolet-visible spectroscopy systems such as the 1050, 1100 and 1200 Series HPLC system and the 8453 and 8454 single-beam diode array detector spectrophotometers. It is an evolution of the Hewlett-Packard ChemStation System. Two versions are available: one ("online") in connection with the modules of the HPLC chain is designed to control instruments and run experiments, and the other ("offline"), without a connection with the HPLC chain, is designed to analyze data. ChemStation is structured around a number of registers. Two of the more important registers are CHROMREG and CHROMRES, the chromatographic data registers. Other special registers exist for the UV-vis implementation of the software. ChemStation has a command line interpreter and can run macros. Those macros are files grouping a set of commands. These files possess a .mac extension. ChemStation can import analysis lists and export result files in XML by adding new lines to the ChemStation.ini configuration file. This is a feature to implement the connection with a Laboratory information management system (LIMS).
Sources: en.wikipedia.org
The peptide is Aib-His-D-2-Nal-D-Phe-Lys-NH2. Two of its residues are non-natural, which slows enzymatic degradation. The C-terminal amide is common among bioactive peptides.
It binds the same ghrelin receptor but with greater selectivity in functional assays. Preclinical work reports less cortisol and prolactin stimulation at growth-hormone-releasing doses. Those differences are relative, not absolute, and depend on dose and model.
No major regulatory authority has approved it for human therapeutic use. It is sold as a research chemical for laboratory investigation. Clinical status varies by country and is subject to change.
Dry powder is typically kept frozen, desiccated, and protected from light. Avoiding moisture exposure and large temperature swings helps slow degradation. Storage recommendations vary by supplier and should be followed for the specific material.